Welcome to our dedicated page for Arrowroot Acquisition news (Ticker: ARRWU), a resource for investors and traders seeking the latest updates and insights on Arrowroot Acquisition stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arrowroot Acquisition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arrowroot Acquisition's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Arrowroot Acquisition Corp. (Nasdaq: ARRWU) announced that holders of its initial public offering units, totaling 250 million, can now separately trade shares of Class A common stock and warrants starting April 22, 2021. The Class A common stock and warrants will trade under the symbols 'ARRW' and 'ARRWW', respectively. Cantor served as the sole book-running manager for the offering, which received SEC approval on March 1, 2021. The press release emphasizes that it does not constitute an offer to sell securities and includes a caution regarding forward-looking statements.